Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of ruxolitinib plus ACT001 in myelofibrosis with poor response to ruxolitinib
ChiCTR2300067517Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Nov 2022
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dimethylaminomicheliolide and ruxolitinib in myelofibrosis (MF), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Spleen size assessment and Myeloproliferative Neoplasm Symptom Assessment Form total symptom score. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
dimethylaminomicheliolideruxolitinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on ChiCTR2300067517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067517.